Sign in
Taking people in SpainPhase 1

Tests mosunetuzumab or glofitamab with CC-220 or CC-99282 in B-cell non-Hodgkin lymphoma

Tests combined treatments in adults with a type of blood cancer called B-cell non-Hodgkin lymphoma.

Key facts

Who runs it
F. Hoffmann-La Roche AG
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca, and Valencia, SpainSee the 6 sitesAlso in 1 other country, 5 sites
Registry title
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.
Status
Recruiting
Phase
Phase 1
People taking part
52 people, planned
Started
23 Apr 2026
Expected to end
7 Mar 2029
Type of study
Interventional
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with B-cell non-Hodgkin lymphoma. It tests mosunetuzumab or glofitamab together with CC-220 and CC-99282.

Age
18 years or older
Sex
All sexes can join

Where in Spain

Also in 1 other country, 5 sites

  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainTaking people
  • Clinica Universidad de NavarraMadrid, SpainTaking people
  • Hospital General Universitario Gregorio MarañónMadrid, SpainTaking people
  • Hospital Universitario De SalamancaSalamanca, SpainTaking people
  • Hospital Universitario Y Politecnico La FeValencia, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests mosunetuzumab or glofitamab with CC-220 or CC-99282 in B-cell non-Hodgkin lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
20 October 2026